Meeting
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
Authors
Lee D. Cranmer
University of Washington, Fred Hutchinson Cancer Center, Seattle, WA
Lee D. Cranmer , Elizabeth Trice Loggers , Seth Pollack , Roxanne Moore , Rylee Johnson , Shannon Maxwell , Melanie Amador , Michael J Wagner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03660930
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11521)
DOI
10.1200/JCO.2023.41.16_suppl.11521
Abstract #
11521
Poster Bd #
455
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
First Author: Drew W. Rasco
Poster
2018 ASCO Annual Meeting
A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.
First Author: Wen Wee Ma
Poster
2018 ASCO Annual Meeting
Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
First Author: Victor Manuel Villalobos